EN | RU
EN | RU

Help Support

Back

Long term safety and efficacy of Sotatercept to treat pulmonary arterial hypertension

Pulmonary arterial hypertension Pulmonary arterial hypertension
Pulmonary arterial hypertension Pulmonary arterial hypertension

This report elucidated Sotatercept's long-term safety and effectiveness in adults having pulmonary arterial hypertension from the phase 2 randomized PULSAR open-label extension period.

See All

Key take away

For the management of pulmonary arterial hypertension, Sotatercept is effective with a good safety profile.

Background

This report elucidated Sotatercept's long-term safety and effectiveness in adults having pulmonary arterial hypertension from the phase 2 randomized PULSAR open-label extension period.

Method

PULSAR was a placebo-controlled, double-blind study followed by an open-label extension. It assessed Sotatercept on top of background pulmonary arterial hypertension therapy. Participants who were initially randomly assigned to the placebo underwent a 1:1 re-randomization to the Sotatercept 0.3 or 0.7 mg kg-1 (placebo-crossed group).

On the other hand, those who were initially assigned to the Sotatercept dose remained to receive that dose (continued-Sotatercept group). All subjects who got  ≥1 dose of Sotatercept had their safety assessed. Alteration in pulmonary vascular resistance between baseline and months 18–24 served as the primary effectiveness outcome. Functional class and six-minute walk distance were the secondary outcomes ascertained. In two predetermined analyses, delayed-start and placebo-crossed, efficacy was assessed regardless of dose.

Result

Out of 106 volunteers recruited in the PULSAR trial, ninety-seven continued into the extension period. In 32 subjects (30.8%), serious treatment-related adverse events were reported. Notably, 10 subjects (9.6%) experienced treatment-emergent adverse events resulting in study discontinuation.

Three (2.9%) individuals perished, however, none were thought to be due to the research medicine. Both primary and secondary endpoints illustrated a remarkable improvement in the placebo-crossed group. In the continued-Sotatercept group, clinical efficacy was maintained.

Conclusion

For the treatment of pulmonary arterial hypertension, the findings of the study favored Sotatercept's long-term safety and durability of clinical benefit.

Source:

The European Respiratory Journal

Article:

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

Authors:

Marc Humbert et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: